Sapu
June 24, 2026
Theater 2
Type: Company Presentation
Focus Area:
Oncology
Sapu is a private biotechnology company with more than 3 years in operation with over 50M funded. We are looking to be listed through an IPO late this year or early next year. The team is led by biotech leaders that developed Abraxane, Cynviloq, and other. Sapu combines Deciparticle drug-delivery engineering with OT-101 TGF-β2 biology: Deciparticles improve how drugs are delivered, while OT-101 targets the tumor microenvironment that often prevents drugs and immune responses from working effectively. Together, they support a platform strategy around better formulation, better tumor access, and better biological control of resistance. Deciparticles we have everolimus (Sapu003) and docetaxel (Sapu006) in phase 1 trials and TGFB2- we have OT-101 in phase 3 trial.
Company HQ City:
San Diego
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2022
Lead Product in Development:
OT-101 = a TGFB2 antisense with six successful clinical trials in PDAC and GBM. In phase 3 against PDAC.
Deciparticles (Sapu003- everolimus; Sapu006- docetaxel) in phase 1 clinical trials
CEO
Vuong Trieu
Development Phase of Lead Product
Phase III
Number of Unlicensed Products Looking for Licensing
6
When you expect your next catalyst update?
in late 2026 or early 2027
What is your next catalyst (value inflection) update?
IPO
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}